Ireland
--:--IST
Latest
Clinical Trials in the USA / NCT07857161
Recruiting Observational

Positron Emission Tomography/Computed Tomography (PECT/CT) Double-Scanning Study

NCT07857161 · tracked via the Priya Life Science USA tracker
Phase
Observational
Started
2026-09-15
Last updated
2026-10-05

Condition(s) studied

PET/CT

Investigational drug(s) / intervention(s)

Omni 128cm PET/CT

Omni 128cm PET/CT: Participants will undergo two PET/CT scans. The first scan will be performed on a commercially available PET/CT system as part of standard clinical care, and the second scan will be performed on the investigational Omni 128 cm PET/CT system. The investigational scan will begin within one hour of completion of the standard-of-care scan. No additional radiopharmaceutical tracer will be administered before the second imaging session.

Study summary

This study aims to collect clinical image data using the Omni 128 cm PET/CT system and compare image quality and performance with clinically indicated PET/CT examinations. Adult participants undergoing a clinically indicated PET/CT scan will also undergo imaging on the Omni 128 cm PET/CT system for research evaluation purposes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Must have a clinical indicated PET/CT exam scheduled including (but not limited to) one of the following radiopharmaceutical tracers: Fluorodeoxyglucose (FDG or 18F-FDG), 18F-DCFPyL; 68Ga- PSMA; 68Ga Dotatate; 18F Amyloid (18F- Florbetapir, 18F-Florbetaben, or 18F-Flutemetamol), or Other standard PET tracers; * Age ≥ 18 years old at time of consent; * Able to provide informed consent; AND, * Has the necessary mental capacity to understand instructions and is able to comply with protocol requirements. Exclusion Criteria: * Who, per the site's SOPs, has any condition that would prevent the clinically indicated PET/CT from proceeding (i.e., pregnancy, breastfeeding, renal impairment, elevated blood glucose, etc.); * Who were previously enrolled in this study; * Who need urgent or emergent care; * Who have any conditions that, in the opinion of the PI or designee, would interfere with the evaluation of the results, constitute a health hazard for the subject; * Unwilling to have GEHC personnel present during scans; OR, * Unable to tolerate the exam.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Stanford University Stanford California Recruiting

More GE Healthcare trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07857161 on ClinicalTrials.gov ↗ ← All trials in the USA